Article Text

S36 Weekly audiograms pre-emptively identify amikacin related ototoxicity in MDR-TB
  1. A Abbara1,
  2. S Lang1,
  3. OM Kon2,
  4. SM Collin3,
  5. D Pan4,
  6. T Hansel2,
  7. R Ravindran4,
  8. R Holder4,
  9. L John1,
  10. RN Davidson1
  1. 1London North West Healthcare NHS Trust, London, UK
  2. 2Imperial NHS Healthcare Trust, London, UK
  3. 3University of Bristol, Bristol, UK
  4. 4Imperial College, London, UK


Introduction and objectives Updated WHO guidance recommends at least 8 months of aminoglycoside (AG) for MDR-TB but provides no definitions or monitoring strategies for otoxocity. Most UK centres perform 2–4 weekly audiograms; we perform weekly audiograms. We retrospectively investigated whether this strategy pre-emptively identifies ototoxicity before significant hearing loss (HL) is evident.

Methods Patients we treated with amikacin for MDR-TB from 2002–2015, with at ≥4 weekly pure tone audiograms, were included. Audiograms, treatment duration, symptoms, creatinine clearance and outcome were obtained from clinical records. All patients received amikacin at 15 mg/kg per day and had weekly amikacin levels and renal function. Definition of HL was defined as per the ASHA as >20 dB loss of pure tone threshold from baseline at one frequency or >10 dB at two adjacent frequencies.

Results 31 MDR-TB patients fulfilled selection criteria; 15 female, median age 36 years (IQR: 24–43) and median weight 61.5 kg (IQR: 52–65.) 22/31 (70.9%) patients had their first audiogram within 10 days; median 5.5 (IQR:4–7.) The median duration of amikacin treatment was 79.5 days (IQR: 61.75–94) and median total dose of 70.8 g (IQR:44.4–97.75.) 4/31 (12.9%) had moderate-severe baseline hearing loss (HL). A total of 17 (54.8%) patients met the ASHA definition of HL: 7 at 4 kHz, 10 at 6 kHz and 17 at 8 kHZ. The median time to meeting ASHA definition of HL among these patients was 59 days (IQR: 41–84.75). 16/31 (51.6%) patients stopped amikacin earlier than planned and 1 continued; 2 (6.5%) due to symptoms of deafness, 2 (6.5%) due to tinnitus and 12 (38.7%) due to asymptomatic high frequency HL on audiograms. Creatinine clearance and trough amikacin levels remained within range for all patients. Regarding outcomes, 17 (54.8%) completed TB treatment, 5 (16.1%) remain on treatment, 4 (12.9%) transferred, 3 (9.7%) were lost to follow up and 1 (3.2%) died.

Conclusions AGs are important in the treatment strategy of MDR-TB but this must be balanced with the long-term side effects. The ototoxicity of AG is unrelated to elevated drug levels or contributing factors and is a common adverse effect. Weekly audiograms led to earlier detection of pre-symptomatic amikacin ototoxicity and cessation in 38.7% of patients.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.